Late-Breaking Phase 1 Liver Metastasis Data from TriSalus Presented at SITC 2023 Supports Developmen

– New data from PERIO-01 clinical trial indicates PEDD™ method resulted in modulation of the tumor microenvironment by enabling performance of the TLR9 agonist, SD-101, in metastatic uveal melanoma, consistent with an earlier presentation from pancreatic adenocarcinoma trial –– Median Progression-Free Survival was 1...

Related Keywords

Texas ,United States ,Denver ,Colorado ,Stevenc Katz ,Sapna Patel ,Trisalu Trinav ,Exchange Commission ,Society Of Immunotherapy ,Nasdaq ,Linkedin ,Twitter ,University Of Texas Md Anderson Cancer Center ,Trisalus Life Sciences ,Median Progression Free Survival ,Disease Control Rate ,Trisalus Life ,Infusion System ,Progression Free Survival ,Chief Medical Officer ,Pressure Enabled Regional Immuno Oncology ,Pressure Enabled Drug Delivery ,Pancreatic Retrograde Venous Infusion System ,Private Securities Litigation Reform Act ,